產(chǎn)品編號 | bs-2637R |
英文名稱 | Rabbit Anti-ERK1 + ERK2 antibody |
中文名稱 | 絲裂原活化蛋白激酶1/2抗體 |
別 名 | ERK1/2; ERK1+ERK2; ERK1/ERK2; ERK 1; ERK 2; ERK-2; ERK1; ERK2; ERT1; ERT2; Extracellular signal regulated kinase 1; Extracellular signal regulated kinase 2; Extracellular signal-regulated kinase 2; HS44KDAP; HUMKER1A; Insulin stimulated MAP2 kinase; MAP kinase 1; MAP kinase 2; MAP kinase isoform p42; MAP kinase isoform p44; MAPK 1; MAPK 2; MAPK 3; MAPK1; MAPK2; MAPK3; MGC20180; Microtubule associated protein 2 kinase; Mitogen activated protein kinase 1; Mitogen activated protein kinase 2; Mitogen activated protein kinase 3; Mitogen-activated protein kinase 1; Mitogen-activated protein kinase 2; MK03_HUMAN; MK01_HUMAN; p38; p40; p41; p41mapk; p42 MAPK; p42-MAPK; p42MAPK; p44 ERK1; p44 MAPK; p44ERK1; p44MAPK; PRKM 1; PRKM 2; PRKM 3; PRKM1; PRKM2; PRKM3; Protein kinase mitogen activated 1; Protein kinase mitogen activated 2; Protein kinase mitogen activated 3; Protein tyrosine kinase ERK 2. |
Specific References (53) | bs-2637R has been referenced in 53 publications.
|
|
研究領(lǐng)域 | 腫瘤 免疫學(xué) 信號轉(zhuǎn)導(dǎo) 生長因子和激素 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 |
抗體來源 | Rabbit |
克隆類型 | Polyclonal |
交叉反應(yīng) | Human,Mouse,Rat (predicted: Rabbit,Pig,Sheep,Cow,Chicken,Dog,Goat,Horse) |
產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
細胞定位 | 細胞核 細胞漿 |
性 狀 | Liquid |
濃 度 | 1mg/ml |
免 疫 原 | KLH conjugated synthetic peptide derived from human ERK1/2: 251-358/358 |
亞 型 | IgG |
純化方法 | affinity purified by Protein A |
緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
PubMed | PubMed |
產(chǎn)品介紹 |
The protein encoded by this gene is a member of the MAPkinase family. MAP kinases, also known as extracellularsignal-regulated kinases (ERKs), act in a signaling cascade thatregulates various cellular processes such as proliferation,differentiation, and cell cycle progression in response to avariety of extracellular signals. This kinase is activated byupstream kinases, resulting in its translocation to the nucleuswhere it phosphorylates nuclear targets. Alternatively splicedtranscript variants encoding different protein isoforms have beendescribed. [provided by RefSeq, Jul 2008]. Function: Serine/threonine kinase which acts as an essentialcomponent of the MAP kinase signal transduction pathway. MAPK1/ERK2and MAPK3/ERK1 are the 2 MAPKs which play an important role in theMAPK/ERK cascade. They participate also in a signaling cascadeinitiated by activated KIT and KITLG/SCF. Depending on the cellularcontext, the MAPK/ERK cascade mediates diverse biological functionssuch as cell growth, adhesion, survival and differentiation throughthe regulation of transcription, translation, cytoskeletalrearrangements. The MAPK/ERK cascade plays also a role ininitiation and regulation of meiosis, mitosis, and postmitoticfunctions in differentiated cells by phosphorylating a number oftranscription factors. About 160 substrates have already beendiscovered for ERKs. Many of these substrates are localized in thenucleus, and seem to participate in the regulation of transcriptionupon stimulation. However, other substrates are found in thecytosol as well as in other cellular organelles, and those areresponsible for processes such as translation, mitosis andapoptosis. Moreover, the MAPK/ERK cascade is also involved in theregulation of the endosomal dynamics, including lysosome processingand endosome cycling through the perinuclear recycling compartment(PNRC); as well as in the fragmentation of the Golgi apparatusduring mitosis. The substrates include transcription factors (suchas ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements(such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1),regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3,MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and avariety of other signaling-related molecules (like ARHGEF2, DCC,FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1,RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1,MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) andphosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are othersubstrates which enable the propagation the MAPK/ERK signal toadditional cytosolic and nuclear targets, thereby extending thespecificity of the cascade. Mediates phosphorylation of TPR inrespons to EGF stimulation. May play a role in the spindle assemblycheckpoint. Phosphorylates PML and promotes its interaction withPIN1, leading to PML degradation (By similarity). Acts as a transcriptional repressor. Binds to a[GC]AAA[GC] consensus sequence. Repress the expression ofinterferon gamma-induced genes. Seems to bind to the promoter ofCCL5, DMP1, IFIH1, IFITM1, IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 andSTAT1. Transcriptional activity is independent of kinase activity. Subunit: Binds both upstream activators and downstream substratesin multimolecular complexes. Interacts with ADAM15, ARHGEF2, ARRB2,DAPK1 (via death domain), HSF4, IER3, IPO7, DUSP6, NISCH, SGK1, andisoform 1 of NEK2. Interacts (via phosphorylated form) with TPR(via C-terminus region and phosphorylated form); the interactionrequires dimerization of MAPK1/ERK2 and increases following EGFstimulation. Interacts (phosphorylated form) withCAV2 ('Tyr-19'-phosphorylated form); the interaction, promoted byinsulin, leads to nuclear location and MAPK1 activation. Interacts with DCC. Interacts withMORG1, PEA15 and MKNK2. MKNK2 isoform 1 binding prevents fromdephosphorylation and inactivation. The phosphorylated forminteracts with PML. Subcellular Location: Cytoplasm, cytoskeleton, spindle. Nucleus. Cytoplasm, cytoskeleton, centrosome. Cytoplasm. Note=Associated with the spindle duringprometaphase and metaphase. PEA15-binding andphosphorylated DAPK1 promote its cytoplasmic retention.Phosphorylation at Ser-244 and Ser-246 as well asautophosphorylation at Thr-188 promote nuclear localization. Tissue Specificity: Widely expressed. Post-translational modifications: Dually phosphorylated on Thr-183 and Tyr-185, which activatesthe enzyme. Ligand-activated ALK induces tyrosine phosphorylation. Dephosphorylated by PTPRJ at Tyr-185. Phosphorylated upon FLT3 and KIT signaling. Similarity: Belongs to the protein kinase superfamily. CMGCSer/Thr protein kinase family. MAP kinase subfamily. Contains 1 protein kinase domain. SWISS: P63085 Gene ID: 5595 Database links: Entrez Gene: 5594 Human Entrez Gene: 5595 Human Entrez Gene: 26413 Mouse Entrez Gene: 26417 Mouse Omim: 176948 Human Omim: 601795 Human SwissProt: P27361 Human SwissProt: P28482 Human SwissProt: P63085 Mouse SwissProt: Q63844 Mouse Unigene: 431850 Human Unigene: 861 Human Unigene: 196581 Mouse Unigene: 8385 Mouse Unigene: 2592 Rat Unigene: 34914 Rat 激酶和磷酸酶(Kinases and Phosphatases) 絲裂原活化蛋白激酶-ERK1/2(Mitogen-activated protein kinase 1/2)是一組可以被多種細胞外信號即獲得蛋白絲/蘇氨酸激酶,處于胞漿信號傳導(dǎo)通路的終末位置,活化后轉(zhuǎn)位到核內(nèi),作用于核內(nèi)轉(zhuǎn)錄因子,調(diào)節(jié)基因表達。它主要參與生長因子、激素、細胞因子、應(yīng)激等各種刺激下細胞的反應(yīng)、細胞的生長、分化過程. |
產(chǎn)品圖片 |
Sample:
Lane 1: A431 (Human) Cell Lysate at 30 ug
Lane 2: Cerebrum (Mouse) Lysate at 40 ug
Lane 3: Cerebrum (Rat) Lysate at 40 ug
Lane 4: Lymph node (Mouse) Lysate at 40 ug
Lane 5: Lymph node (Rat) Lysate at 40 ug
Lane 6: SiHa (Human) Cell Lysate at 30 ug
Lane 7: HUVEC (Human) Cell Lysate at 30 ug
Primary: Anti-ERK1 + ERK2 (bs-2637R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 44’42 kD
Observed band size: 38 kD
Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (ERK1 + ERK2) Polyclonal Antibody, Unconjugated (bs-2637R) at 1:500 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.
Tissue/cell: HUVEC cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (ERK1 + ERK2) Polyclonal Antibody, Unconjugated (bs-2637R) 1:100, 90 minutes at 37°C; followed by a conjugated Goat Anti-Rabbit IgG antibody (bs-0295G-FITC) at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.
Tissue/cell: HUVEC cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (ERK1 + ERK2) Polyclonal Antibody, Unconjugated (bs-2637R) 1:100, 90 minutes at 37°C; followed by a conjugated Goat Anti-Rabbit IgG antibody (bs-0295G-FITC) at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.
|
1、抗體溶解方法 | |
2、抗體修復(fù)方式 | |
3、常用試劑的配制 | |
4、免疫組化操作步驟 | |
5、免疫組化問題解答 | |
6、Western Blotting 操作步驟 | |
7、Western Blotting 問題解答 | |
8、關(guān)于肽鏈的設(shè)計 | |
9、多肽的溶解與保存 | |
10、酶標抗體效價測定程序 | |